Johnson & Johnson agreed to acquire clinical-stage biotech Ollin Biosciences in a deal worth up to $3.325 billion, including milestones, to deepen its ophthalmology pipeline. The acquisition targets additional late-stage and platform-driven capabilities as J&J builds out its eye-care roster. The transaction highlights continued large-pharma willingness to buy clinical-stage assets in ophthalmology, where differentiation and durability of efficacy/safety profiles drive long-term commercial positioning.
Get the Daily Brief